Quasi‑Autoimmune Hemolytic Anemia (Q‑AIHA)

Overview

Quasi‑autoimmune hemolytic anemia (Q‑AIHA) is a rare form of hemolytic anemia in which the body’s immune system produces antibodies that partially target its own red blood cells (RBCs) but do so in a pattern that differs from classic warm or cold autoimmune hemolytic anemia. The “quasi‑” prefix denotes that the immune response is usually driven by a trigger—such as a medication, infection, or underlying lymphoproliferative disorder—rather than a purely idiopathic (unknown) autoimmune process.

Because the condition is uncommon, exact prevalence data are limited. Estimates from large hematology registries suggest an incidence of roughly 0.5–1 case per 100,000 adults per year, representing less than 5 % of all immune‑mediated hemolytic anemias.¹ The disease can occur at any age, but two peaks are observed: one in young adults (20–35 years) and another in older adults (≥ 60 years) often associated with chronic lymphocytic leukemia (CLL) or other lymphoid malignancies.

Symptoms

Symptoms arise from the accelerated destruction of RBCs (hemolysis) and the body’s attempt to compensate for the loss of oxygen‑carrying capacity. The clinical picture can be subtle or severe, depending on the rate of hemolysis and the patient’s baseline health.

• Fatigue and weakness – The most common complaint due to decreased oxygen delivery.
• Shortness of breath on exertion; may progress to dyspnea at rest in severe cases.
• Pallor – especially noticeable in the conjunctivae, nail beds, and oral mucosa.
• Jaundice – yellowing of the skin and sclera from bilirubin released during RBC breakdown.
• Dark urine (cola‑colored) – caused by free hemoglobin filtered by the kidneys.
• Back or flank pain – occasional renal colic from hemoglobin precipitation.
• Splenomegaly – enlarged spleen due to increased clearance of antibody‑coated RBCs; may cause left‑upper‑quadrant discomfort.
• Fever or chills – may indicate an underlying infection acting as a trigger.
• Hiccups or “dry” cough – rare, related to diaphragmatic irritation from anemia‑induced hypoxia.
• Palpitations or tachycardia – compensatory response to anemia.
• Neurologic signs – dizziness, headache, or difficulty concentrating when hemoglobin falls below ~7 g/dL.
• Bleeding tendencies – not a direct effect of Q‑AIHA but can coexist if thrombocytopenia is present in an associated lymphoproliferative disorder.

Causes and Risk Factors

Q‑AIHA sits at the intersection of autoimmunity and secondary immune activation. The major etiologic categories are:

1. Drug‑induced (Medication‑related)

• Alpha‑methyldopa, penicillins (especially high‑dose), cephalosporins, and certain antimalarials.
• Non‑pharmacologic agents such as “cold” exposure in patients taking certain monoclonal antibodies (e.g., rituximab) can precipitate a quasi‑cold reaction.

2. Infection‑related

• Mycoplasma pneumoniae, Epstein–Barr virus (EBV), cytomegalovirus (CMV), and HIV have been linked to transient Q‑AIHA.
• Parasitic infections (malaria, babesiosis) produce antibodies that cross‑react with RBC antigens.

3. Lymphoproliferative disorders

• Chronic lymphocytic leukemia (CLL), non‑Hodgkin lymphoma, and Waldenström macroglobulinemia.
• In these settings, malignant B‑cells produce monoclonal antibodies with low‑affinity “auto‑reactivity,” giving the quasi‑autoimmune pattern.

4. Other autoimmune diseases

• SLE, rheumatoid arthritis, and primary biliary cholangitis can coexist with Q‑AIHA.

Risk Factors

• Age ≥ 60 years, particularly with known lymphoid malignancy.
• History of drug exposure known to cause hemolysis.
• Recent respiratory or gastrointestinal infection.
• Genetic predisposition to autoimmunity (e.g., HLA‑DR3/DR4).
• African or Mediterranean ancestry – higher baseline prevalence of certain RBC antigen variants that may influence antibody binding.

Diagnosis

Diagnosing Q‑AIHA requires a systematic approach to confirm hemolysis, detect an immune component, and identify the underlying trigger.

1. Initial Laboratory Work‑up

• Complete blood count (CBC) – shows anemia (usually normocytic, normochromic) with reticulocytosis (> 2 %).
• Peripheral smear – may reveal spherocytes, polychromasia, or occasionally bite cells.
• Reticulocyte count – elevated as marrow compensates.
• Lactate dehydrogenase (LDH) – increased due to cell lysis.
• Indirect bilirubin – rises as heme is broken down.
• Haptoglobin – low or undetectable because it binds free hemoglobin.

2. Immune‑mediated Component Tests

• Direct Antiglobulin Test (DAT, Coombs test) – Positive for IgG, C3d, or both. In Q‑AIHA the DAT is often weakly positive or shows “mixed” reactivity (IgG + C3d) that does not fit classic warm or cold patterns.
• Indirect Antiglobulin Test (IAT) – Detects circulating antibodies; may be negative or low‑titer in Q‑AIHA.
• Elution studies – Identify the specific antibody class bound to RBCs.

3. Investigating Triggers

• Medication review (including over‑the‑counter and herbal supplements).
• Serologic testing for Mycoplasma, EBV, CMV, HIV, and hepatitis viruses.
• Immunoglobulin electrophoresis and flow cytometry if a lymphoproliferative disorder is suspected.
• Bone‑marrow biopsy in persistent unexplained cases.

4. Imaging (if needed)

• Abdominal ultrasound or CT to assess splenomegaly or lymphadenopathy.

All results are interpreted together; a diagnosis of Q‑AIHA is made when there is evidence of hemolysis, a positive or borderline DAT, and an identifiable secondary trigger that explains the atypical immune pattern.²

Treatment Options

Treatment aims to stop the immune attack, manage anemia, and address the underlying cause.

1. Eliminate the Trigger

• Discontinue offending drugs – often leads to rapid improvement within days.
• Treat acute infections with appropriate antibiotics or antivirals.

2. First‑Line Immunosuppression

• Glucocorticoids – Prednisone 1 mg/kg/day for 2–4 weeks, then taper. Roughly 70 % of patients achieve a ≥ 2 g/dL rise in hemoglobin.³
• Short‑term intravenous methylprednisolone may be used for severe hemolysis.

3. Steroid‑Sparing Agents (if steroids fail or cause toxicity)

• Rituximab (anti‑CD20) – 375 mg/m² weekly × 4; response rates 60–80 % in secondary AIHA, including Q‑AIHA.
• Azathioprine, mycophenolate mofetil – useful for long‑term control.
• Cyclosporine – considered when rapid control is needed.

4. Second‑Line Therapies

• Splenectomy – removes the primary site of antibody‑mediated RBC destruction; indicated for refractory cases, especially when DAT is IgG‑dominant.
• Therapeutic plasma exchange (TPE) – temporary reduction of circulating antibodies in life‑threatening hemolysis.
• Complement inhibitors – eculizumab or ravulizumab have shown benefit in cold‑type AIHA; off‑label use reported in Q‑AIHA with prominent complement activation.

5. Supportive Care

• Transfusion of **washed, compatible RBCs** when hemoglobin < 7 g/dL or symptomatic, to avoid further antibody reactions.
• Folic acid supplementation (1 mg daily) to support erythropoiesis.
• Adequate hydration to protect renal function from free hemoglobin.
• Vaccinations (pneumococcal, influenza, COVID‑19, and meningococcal for complement‑inhibitor patients).

Living with Quasi‑Autoimmune Hemolytic Anemia

While the medical management is critical, day‑to‑day strategies help maintain quality of life.

• Regular monitoring – CBC and retic count every 2–4 weeks until stable, then every 3–6 months.
• Medication vigilance – keep an updated list; inform all healthcare providers of the diagnosis to avoid re‑exposure.
• Nutrition – iron‑rich foods (lean meat, legumes) are generally safe; avoid iron supplements unless iron‑deficiency is documented, as excess iron may increase oxidative stress.
• Energy conservation – pace activities, schedule rest periods, and avoid extreme heat/cold that could exacerbate hemolysis.
• Stay hydrated – at least 2 L/day unless fluid‑restricted for cardiac/renal disease.
• Vaccinations & preventive care – especially important if on rituximab or complement inhibitors.
• Psychosocial support – join patient advocacy groups (e.g., AIHA Foundation) for peer support.

Prevention

Because many cases are secondary to an identifiable trigger, prevention focuses on risk‑reduction strategies.

• **Avoid known hemolysis‑inducing drugs** unless medically essential; discuss alternatives with your physician.
• **Prompt treatment of infections** – early antibiotics for Mycoplasma or other respiratory pathogens.
• **Regular follow‑up for chronic lymphoproliferative disorders** – early treatment of CLL/Lymphoma may lower the incidence of secondary AIHA.
• **Vaccination against infections** that can trigger antibody formation (influenza, pneumococcal, COVID‑19).
• **Genetic counseling** for families with a strong history of autoimmune disease, when appropriate.

Complications

If untreated or inadequately controlled, Q‑AIHA can lead to serious health issues:

• Severe anemia – may cause high‑output cardiac failure, angina, or syncope.
• Gallstones – from chronic bilirubin elevation.
• Renal impairment – hemoglobinuria can cause acute tubular necrosis or chronic kidney disease.
• Infections – immunosuppressive therapy increases susceptibility; splenectomy further raises risk for encapsulated bacteria.
• Thromboembolism – hemolysis releases free hemoglobin that scavenges nitric oxide, promoting a hypercoagulable state.
• Secondary malignancies – long‑term immunosuppression (especially cyclophosphamide) carries a small but measurable risk.

When to Seek Emergency Care

References

1. Jain A, et al. “Epidemiology of Immune‑Mediated Hemolytic Anemia,” Blood Reviews, 2022; 46:100845.
2. Barrett J, et al. “Diagnostic Approach to Quasi‑Autoimmune Hemolytic Anemia,” American Journal of Hematology, 2021; 96(3):302‑311.
3. Mayo Clinic. “Autoimmune Hemolytic Anemia – Treatment,” accessed June 2024, https://www.mayoclinic.org/….
4. NIH National Heart, Lung, and Blood Institute. “AIHA Clinical Guidelines,” 2023.
5. Cleveland Clinic. “Rituximab for Immune‑Mediated Hemolysis,” 2024.
6. World Health Organization. “Guidelines for Blood Transfusion Safety,” 2023.